Key facts
- RainSure Scientific’s last known valuation is $125.0M (Dec 2019).
- It has raised $24.4M; the latest was Later Stage VC in Dec 2024.
- Notable investors include ZhenFund, YuanBio Venture Capital, Future Capital Discovery Fund, Zero2IPO Venture Capital, China-Singapore Suzhou Industrial Park Development Investment — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for RainSure Scientific
- ·The full record, as it builds
Funding rounds
No funding rounds for RainSure Scientific are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RainSure Scientific
Developer and manufacturer of digital polymerase chain reaction (PCR) instruments designed for tumors. The company's platform specializing in technology innovations in microfluidics, engineering, and molecular biology, incorporates microfluidics, optics, precision instruments, electronic engineering, and biochemical technology into their digital PCR instruments, enabling patients to receive early-stage diagnosis of tumors and other diseases and received the treatment they need.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2017
- Employees
- 60
- Website
- rainsurebio.com/
- Ownership
- Privately Held (backing)
RainSure Scientific doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RainSure Scientific shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RainSure Scientific in its N-PORT filings yet. We sweep new filings monthly.